Scientists target senescent "zombie cells" with new drugs called senolytics, which may slow aging and prevent diseases like ...

Q4 2024 Earnings Call Transcript March 13, 2025 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.01, ...

Cantor Fitzgerald reaffirmed their overweight rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...

Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and ...